Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
Cancer Communications · 2023
DOI: 10.1002/cac2.12425 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cancer Communications, 2023. Verfasst von Leena Karimi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
- Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
- St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, New South Wales, Australia.
- Department of Oncology, Institute of Clinical Research, Odense University Hospital, Odense, Denmark.
- Department of Pathology, Sydvestjysk Sygehus, Esbjerg, Denmark.
- Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.
ORCID-Profile: Henrik J Ditzel
Zitieren
APA
Karimi, L., Alves, C. L., Terp, M. G., Tuttolomondo, M., Portman, N., Ehmsen, S., Johansen, L. E., Bak, M., Lim, E., & Ditzel, H. J. (2023). Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor. Cancer Communications. https://doi.org/10.1002/cac2.12425
Vancouver
Karimi L, Alves CL, Terp MG, Tuttolomondo M, Portman N, Ehmsen S, et al. Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor. Cancer Communications. 2023. doi:10.1002/cac2.12425
BibTeX
@article{Karimi2023,
author = {Karimi, Leena and Alves, Carla L and Terp, Mikkel G and Tuttolomondo, Martina and Portman, Neil and Ehmsen, Sidse and Johansen, Lene E and Bak, Martin and Lim, Elgene and Ditzel, Henrik J},
title = {Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor},
journal = {Cancer Communications},
year = {2023},
doi = {10.1002/cac2.12425}
}
EUVIMED